|
JP2018168080A
|
|
Amorphized 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino) benzoyl]-2,3,4,5-tetrahydro-1h-benzoazepine and method for producing the same
|
|
WO2010137160A1
|
|
Prophylactic or therapeutic agent for pulmonary fibrosis
|
|
WO2010086964A1
|
|
Combination therapy for treating cancer
|
|
WO2007091313A1
|
|
Cytokine production inhibitor and heterocyclic phenoxy derivative
|
|
JP2005320346A
|
|
1,3-azole derivative
|
|
US2007208065A1
|
|
Hydroxamic acid derivative and medicine containing the same as active ingredient
|
|
JP2004250401A
|
|
Oxazole derivative
|
|
JP2004250400A
|
|
Pyrimidine derivative
|
|
JP2004231598A
|
|
Crystal polymorphism of nafamostat mesilate and its production method
|
|
WO2004010996A1
|
|
1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
|
|
WO2004011442A1
|
|
Pyrimidine derivatives
|
|
JP2003300876A
|
|
Kit preparation for injection
|
|
WO0194299A1
|
|
Benzene derivatives
|
